Author

Y. Orba

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 8 Biochemistry· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 9 Research Focus:host-pathogen & immune response· 9 Research Focus:drug response / drug discovery· 5 Organism:mouse· 4 Assay:proteomics· 2 Organism:virus· 2 Research Focus:cell type annotation· 1 Assay:cryo-EM· 1

Frequent Co-Authors

M. Sasaki· 10 shared H. Sawa· 9 shared A. Sato· 7 shared K. Tabata· 6 shared S. Toba· 6 shared W. W. Hall· 6 shared K. Uemura· 5 shared H. Nobori· 4 shared

Activity by Year

2021-2023 · peak 6/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

10 shared papersMicrobiology

M. Sasaki

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

Native spike flexibility revealed by BSL3 Cryo-ET of active SARS-CoV-2 virions

H. Fukuhara, H. M. Dokainish, S. Kita, K. Tabata, A. Takasu, J. T. Huiskonen, Y. Anraku, T. Nomai, T. Someya, T. Senda, D. I. Stuart, M. Sasaki, Y. Orba, Y. Suzuki, H. Sawa, K. Maenaka

This study uses cryo-ET to analyze native, active SARS-CoV-2 virions, revealing a transient open-trimer prefusion state and hidden spike flexibility with implications for vaccine design.

bioRxiv · Oct 10, 2023 · PreprintMicrobiology

Combination therapy with oral antiviral and anti-inflammatory drugs improves the efficacy of delayed treatment in severe COVID-19

M. Sasaki, S. Iida, Y. Hirata, S. Kusakabe, K. Konishi, Y. Itakura, K. Tabata, M. Kishimoto, H. Kobayashi, T. Ariizumi, K. Intaruck, H. Nobori, S. Toba, A. Sato, K. Matsuno, , H. Sawa

This study shows that combining an oral antiviral with a corticosteroid improves treatment outcomes in delayed SARS-CoV-2 infection in hamsters compared to monotherapy.

bioRxiv · Jun 20, 2023Microbiology

Morphogenesis of bullet-shaped rabies virus particles requires a functional interplay between the viral matrix protein and ESCRT-I component TSG101

Y. Itakura, K. Tabata, T. Saito, K. Intaruck, N. Kawaguchi, M. Kishimoto, S. Torii, S. Kobayashi, N. Ito, M. Harada, S. Inoue, K. Maeda, A. Takada, W. W. Hall, Y. Orba, , M. Sasaki

This study identifies the interaction between rabies virus matrix protein and TSG101 as essential for bullet-shaped virion formation and efficient budding.

bioRxiv · Dec 16, 2022Microbiology

2-Thiouridine is a broad-spectrum antiviral nucleoside analogue against positive-strand RNA viruses

K. Uemura, H. Nobori, A. Sato, S. Toba, S. Kusakabe, M. Sasaki, K. Tabata, K. Matsuno, N. Maeda, S. Ito, M. Tanaka, Y. Anraku, S. Kita, M. Ishii, K. Kanamitsu, , K. Maenaka

This study identifies 2-thiouridine as a broad-spectrum antiviral against SARS-CoV-2 and other positive-strand RNA viruses by inhibiting viral RNA synthesis.

bioRxiv · Dec 14, 2022Microbiology

Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for SARS-CoV-2 3CL Protease

Y. Hirose, N. Shindo, M. Mori, S. Onitsuka, H. Isogai, R. Hamada, T. Hiramoto, J. Ochi, D. Takahashi, T. Ueda, J. M. M. Caaveiro, Y. Yoshida, S. Ohdo, N. Matsunaga, S. Toba, , A. Ojida

The paper identifies a new class of covalent inhibitors for SARS-CoV-2 3CL protease with chlorofluoroacetamide warhead, showing potent antiviral activity comparable to nirmatrelvir.

bioRxiv · Jun 5, 2022Biochemistry

Oral administration of S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and accelerates recovery from clinical aspects of COVID-19

M. Sasaki, K. Tabata, M. Kishimoto, Y. Itakura, H. Kobayashi, T. Ariizumi, K. Uemura, S. Toba, S. Kusakabe, Y. Maruyama, S. Iida, N. Nakajima, T. Suzuki, S. Yoshida, H. Nobori, , H. Sawa

This study shows that oral S-217622 reduces SARS-CoV-2 viral load and improves recovery in hamsters, with activity against multiple variants.

bioRxiv · Feb 14, 2022Microbiology

Virological characteristics of SARS-CoV-2 BA.2 variant

D. Yamasoba, I. Kimura, H. Nasser, Y. Morioka, N. Nao, J. Ito, K. Uriu, M. Tsuda, J. Zahradnik, K. Shirakawa, R. Suzuki, M. Kishimoto, Y. Kosugi, K. Kobiyama, T. Hara, , Sawa

This study compares the virological characteristics of SARS-CoV-2 BA.2 and BA.1 variants, finding BA.2 has higher transmissibility, different antigenicity, greater replicative capacity, and higher pathogenicity in hamsters.

bioRxiv · Feb 14, 2022Microbiology

Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19

Y. Unoh, S. Uehara, K. Nakahara, H. Nobori, Y. Yamatsu, S. Yamamoto, Y. Maruyama, Y. Taoda, K. Kasamatsu, T. Suto, K. Kouki, A. Nakahashi, S. Kawashima, T. Sanaki, S. Toba, , Y. Tachibana

This paper describes the discovery of S-217622, an oral non-covalent SARS-CoV-2 3CL protease inhibitor showing antiviral activity and favorable pharmacokinetics in preclinical studies.

bioRxiv · Jan 26, 2022Biochemistry

SARS-CoV-2 bearing a mutation at the S1/S2 cleavage site exhibits attenuated virulence and confers protective immunity

M. Sasaki, S. Toba, Y. Itakura, H. M. Herman M. Chambaro, K. Mai, K. Tabata, K. Intaruck, K. Uemura, T. Sanaki, A. Sato, W. W. Hall, Y. Orba, H. Sawa

This study shows that SARS-CoV-2 variants with mutations at the furin cleavage site are less virulent and induce protective immunity in hamsters.

bioRxiv · Apr 29, 2021Microbiology

SARS-CoV-2 variants with mutations at the S1/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells

M. Sasaki, K. Uemura, A. Sato, T. Sanaki, K. Maenaka, W. W. Hall, Y. Orba, H. Sawa

This study shows that SARS-CoV-2 variants with mutations at the S1/S2 cleavage site emerge in TMPRSS2-deficient cells, leading to reduced cell tropism and plaque size.

PLOS Pathogens · Jan 21, 2021Peer-reviewedMicrobiology